Clinical trials: Dermatitis Eczema
Atopic Dermatitis
Study of CM310 in Children Subjects With Moderate-to-severe Atopic Dermatis
This is a multi-center, single arm, open-label study to evaluate safety in children patients with moderate-to severe atopic dermatis.
- Trial name
- NCT06162507
- Testing
- CM310
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Keymed Biosciences Co.Ltd
Moderate-to-Severe Atopic Dermatitis
Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants With Moderate-to-Severe Atopic Dermatitis
The purpose of this study was to assess the pharmacokinetics (PK), safety, and efficacy of nemolizumab in pediatric participants with moderate-to-severe atopic dermatitis (AD).
- Trial name
- NCT04921345
- Testing
- Nemolizumab
- Where
- 23 sites in United States, Denmark and 3 more
- Volunteers
- 109 people
- Sponsor
- Galderma R&D
Atopic Dermatitis
A Phase II Study in Adult Patients With Moderate to Severe Atopic Dermatitis
This proposed study is a randomized, double-blind, placebo-controlled, 3-arm parallel, multicenter phase II study, designed to explore the efficacy and safety of SHR0302 treatment for patients with moderate to severe atopic…
- Trial name
- NCT04162899
- Testing
- Drug: SHR0302
- Where
- 23 sites in China
- Volunteers
- 105 people
- Sponsor
- Reistone Biopharma Company Limited
Skin Pruritus, Itch
Efficacy and Safety of HA35 Gel for Ultra-Rapid Skin Pruritus Relief
This is a prospective, single-arm, open-label, pilot clinical study to evaluate the efficacy and safety of topical 10% high-concentration 35 kDa hyaluronan (HA35) gel for ultra-rapid relief of moderate-to-severe skin pruritus…
- Conditions
- Skin Pruritus, Itch, Eczema Itch, Neurodermatitis
- Trial name
- HA35-ITCH (NCT07580911)
- Testing
- 10% High-Concentration 35 kDa Hyaluronan (HA35) Topical Anti-Pruritic Gel
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Nakhia Impex LLC
Atopic Dermatitis
A Dose Ranging Placebo-Controlled Double-Blind Study to Evaluate the Safety and Efficacy of Tezepelumab in Atopic Dermatitis
This phase 2b study is designed to evaluate the safety and efficacy of tezepelumab as a monotherapy and explore its efficacy as adjunct therapy in subjects with moderate-to-severe atopic dermatitis (AD).
- Trial name
- NCT03809663
- Testing
- Tezepelumab
- Where
- 86 sites in United States, Australia and 13 more
- Volunteers
- 251 people
- Sponsor
- Amgen
Atopic Dermatitis
Evalution the Safety and Efficacy in Atopic Dermatitis Patients
A multi-center, open, long-term follow-up study to evaluate the efficacy and safety of FURESTEM-AD inj. in patients with moderate to severe chronic atopic dermatitis: 5-year results from the K0102 extension study
- Trial name
- NCT03962387
- Testing
- Not applicable(observational study)
- Where
- South Korea
- Volunteers
- 98 people
- Sponsor
- Kang Stem Biotech Co., Ltd.
Atopic Skin, Children
A Probiotic That Reduces Atopic Skin
To assess the efficacy and safety of the use of probiotics as food supplements in reducing the SCORAD index in children with atopic skin compared with placebo.
- Trial name
- NCT05989295
- Testing
- probiotic LRa05
- Where
- 2 sites in Spain
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Wecare Probiotics Co., Ltd.
Atopic Dermatitis
A Trial of a Botanical Drug Product Containing East Indian Sandalwood Oil (EISO) For Treatment of Atopic Dermatitis
This trial will be a double-blind, randomized, placebo-controlled, safety, tolerability and efficacy trial of SAN007 (5% East Indian sandalwood oil in a cream formulation) treatment regimen when administered daily for up to 28…
- Trial name
- NCT03000595
- Testing
- SAN007 Cream
- Sponsor
- Santalis Pharmaceuticals, Inc.
Atopic Dermatitis
Comparative Study:Topison (Mometasone Furoate) Versus Two Others Mometasone Furoates
Atopic dermatitis is a chronic disease, with outbreaks, predominant in childhood, whose main symptom is pruritus of variable intensity and signs of cutaneous xerosis and eczematous pattern lesions.
- Trial name
- LB2001 (NCT04271007)
- Testing
- Mometasone Furoate
- Where
- Brazil
- Volunteers
- 32 people
- Sponsor
- Libbs Farmacêutica LTDA
Atopic Dermatitis
Open-label Study of Dupilumab in Patients With Atopic Dermatitis
The primary objective is to assess the long-term safety of dupilumab administered in adult participants with atopic dermatitis (AD).
- Trial name
- NCT01949311
- Testing
- Dupilumab
- Where
- 432 sites in United States, Australia and 26 more
- Volunteers
- 2,733 people
- Sponsor
- Regeneron Pharmaceuticals
Atopic Dermatitis
Efficacy and Safety of IDP-124 Lotion for the Treatment of Moderate to Severe Atopic Dermatitis in Pediatric and Adult Subjects (301)
Efficacy and Safety of IDP-124 Lotion for the Treatment of Moderate to Severe Atopic Dermatitis in Pediatric and Adult Subjects
- Trial name
- NCT03002571
- Testing
- IDP-124 Lotion, IDP-124 Vehicle Lotion
- Where
- United States
- Volunteers
- 338 people, healthy volunteers welcome
- Sponsor
- Bausch Health Americas, Inc.
Atopic Dermatitis Eczema
Metal Panel Allergen Patch Test Study
Metal allergen patch test study.
- Trial name
- NCT04500834
- Testing
- Metal Panel T.R.U.E. Test
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Allerderm
Atopic Dermatitis Eczema
Safety and Efficacy Study of EVO101 Topical Cream in Atopic Dermatitis
This is a Phase 2a safety and efficacy study of EVO101 for the treatment of adults with atopic dermatitis
- Trial name
- NCT05579899
- Testing
- EVO101
- Where
- 21 sites in United States
- Volunteers
- 119 people
- Sponsor
- Evommune, Inc.
Atopic Dermatitis (AD)
Effect of Partially Hydrolyzed Formula With Synbiotics on Skin Barrier Function
The main purpose of this study is to assess the efficacy of a partially hydrolyzed formula with synbiotics in halting one of the first steps of the allergic march (atopic dermatitis) in infants at risk of allergy.
- Trial name
- SPHINX (NCT06943469)
- Testing
- Test formula, Control formula
- Where
- 25 sites in Belgium, France and 3 more
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Société des Produits Nestlé (SPN)
Atopic Dermatitis
An Evaluation of PDI-192 0.1% in Comparison to PDI-192 0.15% in the Treatment of Mild to Moderate Atopic Dermatitis
This study will compare the safety and efficacy of three test article foams (PDI-192 0.1% Foam, PDI-192 0.15% Foam, and Vehicle Foam) such that a final commercial product may be selected for future development.
- Trial name
- NCT01826461
- Testing
- PDI-192, Vehicle
- Where
- 9 sites in United States
- Volunteers
- 151 people
- Sponsor
- PreCision Dermatology, Inc.
Atopic Dermatitis
Safety, Tolerability, and Pharmacokinetic Study of QLM3003 in Healthy Adult Subjects
The purpose of the study is to evaluate the safety and tolerability of single ascending (SAD) doses of QLM3003 compared to placebo. Also, pharmacokinetics (PK) of qlm3003 will be evaluated.
- Trial name
- NCT05932888
- Testing
- QLM3003
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Eczema
Effectiveness of Polymyxin B Sulphate + Prednisolone + Benzocaine + Clioquinol in Acute and Sub-acute Dermatitis Eczematous
Dermatitis eczematous is a recurrent pruritic skin disorder which has a significant morbidity and impaired quality of life due specially pruritus and physical visible skin lesions.
- Trial name
- NCT01429701
- Testing
- polymyxin B sulphate + prednisolone + benzocaine + clioquinol, betamethasone + gentamicin + tolnaftato + cleoquinol
- Volunteers
- 76 people
- Sponsor
- EMS
Normal Volunteers, Atopic Dermatitis (AD)
Safety, Tolerability and PK of ATTO-3712 in Healthy Volunteers and Patients With Atopic Dermatitis
The goal of this clinical trial is to assess the safety, tolerability, and pharmacokinetics of ATTO-3712 in healthy adults and patients with atopic dermatitis.
- Conditions
- Normal Volunteers, Atopic Dermatitis (AD), Atopic Eczema, Atopic Eczema/Dermatitis (Non-Specific)
- Trial name
- NCT07205081
- Testing
- ATTO-3712
- Where
- 17 sites in United States, Canada and 1 more
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Attovia Therapeutics Inc
Atopic Dermatitis
A Single-center, Randomized, Double-blinded, Placebo-controlled, Phase 1 Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of NCP112
To evaluate safety, tolerability and pharmacokinetics of NCP 112 after single and multiple applications on the skin of healthy male volunteers.
- Trial name
- NCT05638165
- Testing
- NCP112
- Where
- South Korea
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- NovaCell Technology Inc.
Atopic Eczema
A Study to Evaluate the Emollient Performance of Doublebase Once in the Treatment of Atopic Eczema
A 4 week, open label, multi-centre (GP setting), post market clinical follow-up study with Doublebase Once in patients of any age and any severity of atopic eczema.
- Trial name
- NCT06453512
- Testing
- Doublebase Once
- Where
- United Kingdom
- Volunteers
- 65 people
- Sponsor
- Dermal Laboratories Ltd
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.